Company intelligence / Profile preview
Newleos Therapeutics
Boston, Massachusetts, United Statesnewleos.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program NTX-1955 has completed Phase 1 trials including single and multiple ascending dose studies, drug-drug interaction, and receptor occupancy studies, demonstrating it is safe, well tolerated, brain penetrant, and selective to GABAA-γ1. The company plans to investigate NTX-1955 in proof-of-concept clinical studies for generalized anxiety disorder in 2025.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Oral small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Roche (licensed assets from)
Beyond the preview
Go deeper on Newleos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Newleos Therapeutics.